Proportion of participants with solicited local adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): pain at injection site, redness, induration, and swelling.;Proportion of participants with solicited systemic adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): fever, fatigue, headache, chills, vomiting, nausea, diarrhea, new or worsened muscle pain, new or worsened joint pain.;Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) throughout the study;Proportion of participants with unsolicited treatment-emergent adverse events throughout the study

Proportion of participants with solicited local adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): pain at injection site, redness, induration, and swelling.;Proportion of participants with solicited systemic adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): fever, fatigue, headache, chills, vomiting, nausea, diarrhea, new or worsened muscle pain, new or worsened joint pain.;Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) throughout the study;Proportion of participants with unsolicited treatment-emergent adverse events throughout the study